The US HAEA provides any clinical trial information provided to us by our pharmaceutical sponsors immediately upon receipt.
A bradykinin antagonist receptor (Firazyr) is being evaluated for the treatment of acute attacks in children with Hereditary Angioedema (HAE).
A new phase III registration trial is open to patients with frequent attacks of HAE. The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin (subcutaneously) of patients with hereditary angioedema. The study will measure the number of hereditary angioedema attacks that patients experience while receiving C1-INH versus placebo subcutaneously. All patients will be able to take on-demand medication for acute attacks at any time during the study. The study is sponsored by CSL Behring. Further information about the trial can be found here: http://clinicaltrials.gov/show/NCT01912456
An oral kallikrein inhibitor is being evaluated as a prophylactic treatment in adults with Hereditary Angioedema (HAE). The purpose of the study is to assess whether treatment with the study drug reduces the frequency of attacks compared to placebo. Each patient will participate in a 12-week dosing period and will be asked to come to the research clinic 6 times over a 4- 6 month period. Patients will record their HAE attacks and study drug dosing in an electronic diary daily. Patients should have access to and take their on-demand treatment for acute attacks at any time as needed during the study. Additional information about the study can be found at http://clinicaltrials.gov/ct2/show/NCT02303626?term=bcx4161&rank=3
If you are interested in participating in this trial, please contact US HAEA’s , (972) 984-0621. Please return to this page often to check for updates. And contact any of our Patient Services Representatives to learn about all of the new FDA-approved HAE therapies, as well as treatments still under development, that can revolutionize HAE patients’ lives.